Cullinan Therapeutics and Taiho have a significant market opportunity with zipalertinib after successful results in the Phase I/II REZILIENT1 trial among previously treated non-small cell lung cancer (NSCLC) patients whose disease harbors epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
The companies announced topline results on 28 January of the Phase IIb portion of the trial for zipalertinib, also known as CLN-081 and TAS6417, saying that it met the primary...
Key Takeaways
- Cullinan and Taiho announced positive topline results from the Phase I/II REZILIENT1 trial of zipalertinib.
- The companies plan to present data from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?